238 related articles for article (PubMed ID: 28425820)
1. Metastatic soft tissue sarcoma: current treatment landscape and future perspectives.
Skafida E; Kokkali S; Nikolaou M; Digklia A
Expert Rev Anticancer Ther; 2017 Jun; 17(6):537-543. PubMed ID: 28425820
[TBL] [Abstract][Full Text] [Related]
2. Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas.
Mohindra N; Agulnik M
Expert Opin Investig Drugs; 2015; 24(11):1409-18. PubMed ID: 26289790
[TBL] [Abstract][Full Text] [Related]
3. Investigational therapies in phase II clinical trials for the treatment of soft tissue sarcoma.
Martin-Liberal J; Pérez E; García Del Muro X
Expert Opin Investig Drugs; 2019 Jan; 28(1):39-50. PubMed ID: 30513001
[TBL] [Abstract][Full Text] [Related]
4. Potential combination chemotherapy approaches for advanced adult-type soft-tissue sarcoma.
Kopp HG; Patel S; Brücher B; Hartmann JT
Am J Clin Dermatol; 2008; 9(4):207-17. PubMed ID: 18572972
[TBL] [Abstract][Full Text] [Related]
5. Newer medical therapies for metastatic soft tissue sarcoma.
Tiwari A; Gupta VG; Bakhshi S
Expert Rev Anticancer Ther; 2017 Mar; 17(3):257-270. PubMed ID: 28103739
[TBL] [Abstract][Full Text] [Related]
6. Next frontiers in systemic therapy for soft tissue sarcoma.
Yen CC; Chen TW
Chin Clin Oncol; 2018 Aug; 7(4):43. PubMed ID: 30173533
[TBL] [Abstract][Full Text] [Related]
7. Standard treatment and emerging drugs for managing synovial sarcoma: adult's and pediatric oncologist perspective.
Baldi GG; Orbach D; Bertulli R; Magni C; Sironi G; Casanova M; Ferrari A
Expert Opin Emerg Drugs; 2019 Mar; 24(1):43-53. PubMed ID: 30841761
[TBL] [Abstract][Full Text] [Related]
8. Systemic treatment in advanced soft tissue sarcoma: what is standard, what is new.
Frezza AM; Stacchiotti S; Gronchi A
BMC Med; 2017 Jun; 15(1):109. PubMed ID: 28571564
[TBL] [Abstract][Full Text] [Related]
9. Advances and controversies in the management of soft tissue sarcomas.
Demetri GD; Blay JY; Casali PG
Future Oncol; 2017 Jan; 13(1s):3-11. PubMed ID: 27918199
[TBL] [Abstract][Full Text] [Related]
10. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG).
Sleijfer S; Ouali M; van Glabbeke M; Krarup-Hansen A; Rodenhuis S; Le Cesne A; Hogendoorn PC; Verweij J; Blay JY
Eur J Cancer; 2010 Jan; 46(1):72-83. PubMed ID: 19853437
[TBL] [Abstract][Full Text] [Related]
11. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
[TBL] [Abstract][Full Text] [Related]
12. Current trials and new aspects in soft tissue sarcoma of adults.
Issels RD; Schlemmer M
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S4-8. PubMed ID: 12042982
[TBL] [Abstract][Full Text] [Related]
13. First-line treatment in advanced or metastatic disease: one size fits all or adapted to specific histiotypes?
Seddon B
Curr Opin Oncol; 2016 Jul; 28(4):323-30. PubMed ID: 27153355
[TBL] [Abstract][Full Text] [Related]
14. Pazopanib in the treatment of soft tissue sarcoma.
Schöffski P
Expert Rev Anticancer Ther; 2012 Jun; 12(6):711-23. PubMed ID: 22716487
[TBL] [Abstract][Full Text] [Related]
15. Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.
Gelderblom H; Blay JY; Seddon BM; Leahy M; Ray-Coquard I; Sleijfer S; Kerst JM; Rutkowski P; Bauer S; Ouali M; Marreaud S; van der Straaten RJ; Guchelaar HJ; Weitman SD; Hogendoorn PC; Hohenberger P
Eur J Cancer; 2014 Jan; 50(2):388-96. PubMed ID: 24215845
[TBL] [Abstract][Full Text] [Related]
16. Advances of systemic treatment for adult soft-tissue sarcoma.
Liu W; Jiang Q; Zhou Y
Chin Clin Oncol; 2018 Aug; 7(4):42. PubMed ID: 30173532
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacology, drug-drug interactions and safety of pazopanib: a review.
Boudou-Rouquette P; Tlemsani C; Blanchet B; Huillard O; Jouinot A; Arrondeau J; Thomas-Schoemann A; Vidal M; Alexandre J; Goldwasser F
Expert Opin Drug Metab Toxicol; 2016 Dec; 12(12):1433-1444. PubMed ID: 27556889
[TBL] [Abstract][Full Text] [Related]
18. First-line anthracycline-based chemotherapy for angiosarcoma and other soft tissue sarcoma subtypes: pooled analysis of eleven European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group trials.
Young RJ; Natukunda A; Litière S; Woll PJ; Wardelmann E; van der Graaf WT
Eur J Cancer; 2014 Dec; 50(18):3178-86. PubMed ID: 25459395
[TBL] [Abstract][Full Text] [Related]
19. Olaratumab for the treatment of advanced soft tissue sarcoma.
Okuno SH; Maran A; Robinson SI
Expert Rev Anticancer Ther; 2017 Oct; 17(10):883-887. PubMed ID: 28862476
[TBL] [Abstract][Full Text] [Related]
20. Systematic therapy for unresectable or metastatic soft-tissue sarcomas: past, present, and future.
Morgan SS; Cranmer LD
Curr Oncol Rep; 2011 Aug; 13(4):331-49. PubMed ID: 21633784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
